In a stable patient with PE who has right heart strain or elevated biomarkers, what risk category are they and what is the initial therapy?

In a stable patient with PE who has right heart strain or elevated biomarkers, what risk category are they and what is the initial therapy?

• A. High risk; Reperfusion therapy plus anticoagulation
• B. Low risk; Anticoagulation only
• C. Intermediate risk; Just anticoagulation therapy
• D. Low risk; Antiplatelet therapy only

Answer: (C)

The important concept is risk stratification in pulmonary embolism. If a patient is stable (no shock or hypotension) but shows right heart strain on imaging or has elevated biomarkers (like troponin or BNP), they are categorized as intermediate-risk (submassive). In this group, the initial therapy is anticoagulation to stop clot propagation and allow natural dissolution, with close monitoring for any signs of deterioration. Reperfusion therapy (thrombolysis or similar) is not given upfront in stable patients unless they worsen or develop hemodynamic instability. Antiplatelet therapy alone isn’t appropriate for acute PE. So, the best choice is intermediate risk with initial anticoagulation.

The important concept is risk stratification in pulmonary embolism. If a patient is stable (no shock or hypotension) but shows right heart strain on imaging or has elevated biomarkers (like troponin or BNP), they are categorized as intermediate-risk (submassive). In this group, the initial therapy is anticoagulation to stop clot propagation and allow natural dissolution, with close monitoring for any signs of deterioration. Reperfusion therapy (thrombolysis or similar) is not given upfront in stable patients unless they worsen or develop hemodynamic instability. Antiplatelet therapy alone isn’t appropriate for acute PE. So, the best choice is intermediate risk with initial anticoagulation.